Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.

Qayyum AA., Mouridsen M., Nilsson B., Gustafsson I., Schou M., Nielsen OW.

Randomized Controlled Trial with a reported sample of 54 on Cardiovascular Disease, Stroke Research, published in ESC Heart Fail (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
ESC Heart Fail (2023)
Country
England
Reported sample size
54
Source database
PubMed
PMID
36638837
PMCID
PMC10053281
DOI
10.1002/ehf2.14281
NCT
NCT03092284
Citations
43

Abstract (original English)

Aims Patients suffering from chronic ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) have reduced quality-of-life, repetitive hospital admissions, and reduced life expectancy. Allogeneic cell therapy is currently investigated as a potential treatment option after initially encouraging results from clinical autologous and allogeneic trials in patients with HFrEF. We aimed to investigate the allogeneic Cardiology Stem Cell Centre Adipose tissue derived mesenchymal Stromal Cell product (CSCC_ASC) as an add-on therapy in patients with chronic HFrEF. Methods and results This is a Danish multi-centre double-blinded placebo-controlled phase II study with direct intra-myocardial injections of allogeneic CSCC_ASC. A total of 81 HFrEF patients were included and randomized 2:1 to CSCC_ASC or placebo injections. The inclusion criteria were reduced left ventricular ejection fraction (LVEF ≤ 45%), New York Heart Association (NYHA) class II-III despite optimal anti-congestive heart failure medication and no further revascularization options. Injections of 0.3 mL CSCC_ASC (total cell dose 100 × 10 6 ASCs) (n = 54) or isotonic saline (n = 27) were performed into the viable myocardium in the border zone of infarcted tissue using the NOGA Myostar® catheter (Biological Delivery System, Cordis, Johnson & Johnson, USA). The primary endpoint, left ventricular end systo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMiddle AgedAgedHeart FailureMyocardial IschemiaStroke VolumeVentricular Function, LeftMesenchymal Stem Cell TransplantationMesenchymal Stem CellsDenmark

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research